Artiva Biotherapeutics, Inc. (ARTV)
| Market Cap | 224.67M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -83.87M |
| Shares Out | 24.72M |
| EPS (ttm) | -3.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 195,885 |
| Open | 10.43 |
| Previous Close | 10.75 |
| Day's Range | 9.03 - 10.60 |
| 52-Week Range | 1.47 - 14.53 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 18.67 (+105.39%) |
| Earnings Date | May 13, 2026 |
About ARTV
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/mic... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ARTV stock is "Strong Buy." The 12-month stock price target is $18.67, which is an increase of 105.39% from the latest price.
News
Artiva Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
A novel NK cell therapy for RA is advancing, with upcoming efficacy data in late-line patients and a focus on deep B-cell depletion, safety, and scalability. The approach aims for durable, one-time treatment and first-mover advantage in a significant unmet need population.
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therap...
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026
Artiva Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Deep B-cell depletion is positioned as a transformative approach for autoimmune diseases, with a lead focus on refractory rheumatoid arthritis due to high unmet need and first-mover potential. Early data show strong efficacy, favorable safety, and scalable, community-friendly administration, with pivotal trial plans and FDA discussions set for 2026.
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapi...
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cel...
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cel...
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cel...
Artiva Biotherapeutics Transcript: Jefferies London Healthcare Conference 2025
A novel off-the-shelf NK cell therapy for autoimmune disease shows a strong safety profile and deep B cell depletion, with pivotal RA trial plans and a large market opportunity ahead. Cash reserves support operations into 2027.
Artiva Biotherapeutics Transcript: TD Cowen Immunology and Inflammation Summit
AlloNK, an allogeneic NK cell therapy, is advancing in autoimmune diseases with a focus on rheumatoid arthritis due to its safety, scalability, and robust B cell depletion. Initial efficacy data in RA are expected in the first half of 2026, with a goal of durable responses in refractory patients.
Artiva Biotherapeutics Transcript: Study Update
AlloNK, a non-genetically modified NK cell therapy, showed a favorable safety profile and consistent, deep B-cell depletion in autoimmune patients, with no cell therapy-related toxicities and outpatient feasibility. The therapy targets refractory RA, aiming for robust efficacy and scalability, with pivotal trial discussions planned for next year.
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were t...
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, t...
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, high...
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell thera...
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidat...
Artiva Biotherapeutics Transcript: Cantor Global Healthcare Conference 2025
The session highlighted a non-genetically modified NK cell therapy platform combined with monoclonal antibodies, emphasizing safety, scalable manufacturing, and community-setting compatibility. Key data on B cell depletion and safety will be shared by year-end, with a lead indication and efficacy results to follow.
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therap...
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic scl...
Artiva Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2025
Enhanced NK cell therapies show promising efficacy and safety in oncology, informing autoimmune trial design. Initial efficacy data for AlloNK in autoimmune is delayed to H1 2026 to ensure robust results, with a focus on patient selection, safety, and expanding access to community settings.
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapi...
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy Dr. Banerjee's appointment culminates Artiva's...